Ariana Pelosci, associate editor for CancerNetwork®, has been with the team since June 2021. She specializes both in web and print, and runs the social media for CancerNetwork®.
She is a graduate of the University of Delaware, where she studied Media Communications and minored in journalism and marketing. At heart, she is a Jersey girl, and you can always find her down the shore during her free time.
Ariana loves to read, specifically historical or contemporary fiction. Follow Ariana on Twitter @APelosci or email her at apelosci@mjhlifesciences.com.
Efficacy Improvement Observed in Nivolumab Combo in Advanced GI Cancers
January 18th 2024Results from an observational study found nivolumab plus chemotherapy helped enhance overall survival and progression-free survival for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
Induction Chemotherapy/CRT Improves Efficacy in Advanced Cervical Cancer
November 17th 2023Results from the phase 3 GCIG INTERLACE trial highlight progression-free survival and overall survival improvements with induction chemotherapy plus chemoradiotherapy for patients with locally advanced cervical cancer.
FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer
November 16th 2023Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.
Domvanalimab Plus Zimberelimab Improve Efficacy in Gastrointestinal Cancers
November 7th 2023Results from arm A1 of the phase 2 EDGE-Gastric study indicate that patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma experienced improved responses after receiving domvanalimab/zimberelimab.
Senaparib Significantly Improves PFS Vs Placebo in Advanced Ovarian Cancer
October 20th 2023Results from the phase 3 FLAMES trial show an improved progression-free survival benefit with senaparib monotherapy vs placebo across all pre-specified patient subgroups with newly diagnosed, advanced ovarian cancer.